false
Catalog
The Changing Face of Substance Use: Drug Trends an ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker, a Drug Intelligence Officer for Connecticut, discusses their work within the Overdose Response Strategy (ORS) in New England HIDTA, focusing on drug trends and challenges. They highlight the evolution of the drug landscape, beginning with the OxyContin crisis which transitioned to heroin use, followed by the rise of fentanyl around 2013, significantly altering the drug market from one based on natural sources to synthetic substances.<br /><br />A shift in synthetic drug dominance is noted, with fentanyl being a primary concern due to its high fatality rate, although stimulants like cocaine and methamphetamine also pose significant issues. The discourse covers the complexity of poly-drug use and the illicit drug environment, emphasizing the challenges users face in understanding the composition and risk of substances they consume. The increasing presence of synthetic cannabinoids, carfentanil, and xylosine in drugs exacerbates overdose risks and complicates drug monitoring efforts. The speaker also addresses the prevalence of counterfeit pills disguised as legitimate medications, which pose acute dangers due to their unpredictable content, often involving fentanyl or methamphetamines.
Keywords
Overdose Response Strategy
fentanyl
synthetic drugs
poly-drug use
counterfeit pills
drug trends
Connecticut
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email
PCSS-MOUD
.
ORN
opioidresponsenetwork.org
×
Please select your language
1
English